-+ 0.00%
-+ 0.00%
-+ 0.00%

Maia Biotechnology reports 88% disease control rate in Phase 2 lung cancer trial

PUBT·11/17/2026 13:45:25
Listen to the news
Maia Biotechnology reports 88% disease control rate in Phase 2 lung cancer trial
  • Maia Biotechnology reported updated interim Phase 2 THIO-101 results showing consistent disease control with ateganosine in previously treated advanced non-small cell lung cancer.
  • Expansion results aligned with earlier findings in patients whose cancer resisted chemotherapy and immunotherapy.
  • Further expansion data may support an FDA accelerated approval filing for the therapy, which holds Fast Track designation.
  • The pivotal Phase 3 THIO-104 trial is progressing toward an interim survival analysis in 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611170845PRIMZONEFULLFEED9878685) on November 17, 2026, and is solely responsible for the information contained therein.